As of Dec 02
| +0.46 / +1.43%|
The 16 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 68.00, with a high estimate of 106.00 and a low estimate of 46.00. The median estimate represents a +108.21% increase from the last price of 32.66.
The current consensus among 16 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.